...New York Sen. Charles Schumer questioned whether Bayer could meet soaring demand for the potent anthrax antibiotic and called for government action to allow generic production. Sunday, Senate minority leader Trent Lott predicted the Senate would soon take up debate on whether to strip the patent on Bayer's flagship product...For Bayer, a conservative German drug and chemicals conglomerate, it was a harsh introduction to its new life in the world spotlight...the company moved aggressively to tool up Cipro production at its factories, and officials insist they can meet demand. But the company was far less prepared to deal with the political and public-relations challenges that have arisen in the wake of the attacks.